Content
All Posts > Content under Pharma/Biotech
Teva (TEVA) Beats On Q2 Earnings, Misses Sales, Shares Dip
Article By:
Zacks Investment Research
Read
Thursday, August 2, 2018 10:45 AM EDT
Teva’s second-quarter earnings came in at 78 cents per share which beat consensus estimate of 67 cents. Teva posted revenues of $4.70 billion, which missed consensus estimates of $4.76 billion. Sales declined 18%.
In this article: TEVA
DowDuPont (DWDP) Earnings, Revenues Trounce Estimates In Q2
Article By:
Zacks Investment Research
Read
Thursday, August 2, 2018 10:27 AM EDT
The company witnessed higher sales volumes and gains in local prices across all segments and geographic regions. It also gained from new product launches and strong demand across its targeted end-markets.
Acer Therapeutics Announces Pricing Of Underwritten Public Offering
Article By:
NASDAQ GlobeNewswire
Read
Wednesday, August 1, 2018 6:42 PM EDT
Acer Therapeutics Inc. today announced the pricing of its underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $18.00 per share.
In this article: ACER
Seven Dividend Growth Stocks Rewarding Shareholders With A Raise
Article By:
Dividend Growth Investor
Read
Monday, July 30, 2018 2:04 PM EDT
I usually look for companies that managed to boost dividends for at least a decade. For today's review, I am making an exception. These companies may be good fits for my dividend growth portfolio if they are ever available at attractive valuations.
Biotechs Hold And Ignore Rocky Week Of Global Politics - Big Earnings Upcoming… Updates CELG, BIIB, AZN, XBI
Article By:
Rod Raynovich
Read
Saturday, July 28, 2018 9:15 PM EDT
Biotech and Tech stocks teetered near highs for the year despite all the political drama of Putin and Trump at Helsinki, Russian “Spy” at the NRA, Tariffs and Trade War, Brexit Uncertainty, currency volatility and the Powell FED rate hike policy.
Week In Review: Long Hill Capital Closes $265 Million Fund For China Healthcare
Article By:
ChinaBio® Today
Read
Saturday, July 28, 2018 4:14 PM EDT
Long Hill Capital of Beijing and Shanghai, focused the healthcare and consumer sectors, closed its second fund at $265 million. Long Hill said it "significantly exceeded” its funding target, showing the success of its thesis-investing strategy.
AskSlim Market Week - Friday, July 27
Video By:
Steve Miller
Watch
Friday, July 27, 2018 7:08 PM EDT
The stock market continued its winning ways this week but drooping on Friday. Overall, positive earnings have buoyed the stock market despite disappointing earnings from stocks like Facebook and Whirlpool.
AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up
Article By:
Zacks Investment Research
Read
Friday, July 27, 2018 11:00 AM EDT
AbbVie Inc. ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Moreover, the company raised its expectations for 2018 bottom line. However, shares fell almost 1.8% in pre-market trading.
Week In Review: Acletis Raising $457 Million In Hong Kong IPO At $2 Billion Valuation
Article By:
ChinaBio® Today
Read
Saturday, July 21, 2018 4:12 PM EDT
Ascletis BioScience, the Hangzhou biopharma with a novel treatment for hepatitis C, may raise as much as $457 million in its upcoming Hong Kong IPO, a debut offering that values the company at $2 billion.
In this article: MESO
Zynerba Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Friday, July 20, 2018 9:19 PM EDT
Zynerba Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million. Stock is down 24% as a result.
In this article: ZYNE
Biotechs Cruise Onto Green Screen: July Looks Good
Article By:
Rod Raynovich
Read
Thursday, July 19, 2018 12:16 PM EDT
Biotechs cruised through the choppy market of late June to rally with many mid-caps rolling up and major ETFs up creeping toward 2018 highs. However, with earnings reports coming up, we could expect some selling depending on top line growth.
